Achieving Cannabis Cessation -- Evaluating N-Acetylcysteine Treatment (ACCENT)

Kevin Gray, MD
Lead Investigator

Institute of Psychiatry
Medical University of South Carolina (MUSC)

This is a 12-week, intent-to-treat, randomized controlled trial to evaluate the impact of N-Acetylcysteine (NAC) 1200 mg versus matched placebo (PBO) twice daily, added to compliance enhancement (CE) and contingency management (CM) interventions, on cannabis use among treatment-seeking adults (ages 18-50) with cannabis use disorders.  Approximately 300 participants will be randomized to receive NAC 1200 mg or matched placebo twice daily for 12 weeks.  All participants will concurrently receive CE and CM interventions.  CM procedures (weekly during treatment) will include escalating schedules of cash reinforcement with resets, targeting (a) retention/adherence, and (b) cannabis abstinence (confirmed by negative qualitative urine cannabinoid testing).  The primary analysis will evaluate the impact of NAC versus PBO on cannabis use during the 12-week treatment intervention with the primary outcome measure being the odds of negative urine cannabinoid tests submitted during the 12-week treatment, compared between the two treatment groups. 



Publications about CTN-0053 (NCT01675661)

NIDA protocol page

Southern Consortium (Lead) search www
Behavioral Health Services of Pickens County search
New England Consortium search www
APT Foundation search
Ohio Valley Node search www
University of Cincinnati Medical Center search
Pacific Region search www
Integrated Substance Abuse Programs search
Texas search
University of Texas Health Science Center at San Antonio search
Western States search
CODA, Inc. search

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 3/2014 --